Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Targeting leukemic stem cells by Bcl-2 inhibition

Study in laboratory cell cultures, patient samples shows promise

Researchers at The University of Texas M. D. Anderson Cancer Center have found, in laboratory studies, that the experimental drug ABT-737 which has shown promise in some cancers, can destroy acute myeloid leukemia (AML) blast, progenitor and even stem cells that are often resistant to standard chemotherapy treatment.

The drug was powerful in its own right, the researchers say, but they found that some AML cells were themselves resistant to ABT-737, so they added another drug that knocked out this secondary resistance. Together, these agents may provide a powerful therapy against AML, and could form the basis of a new way to treat the cancer, say the scientists, whose study was published in the November 14 issue of the journal, Cancer Cell.

"The combination of these two experimental drugs provides the highest synergistic action I have ever seen against acute myeloid leukemia cells," said the study's lead author, Michael Andreeff, M.D., Ph.D., professor in the Departments of Stem Cell Transplantation and Leukemia.

... more about:
»ABT-737 »AML »Andreeff »Bcl-2 »Mcl-1 »Protein »chemotherapy »leukemia

Although the study was done in laboratory cell cultures and AML cells obtained from patients, Andreeff said he hopes that a combination of these two agents could be tested in eligible patients when they receive standard chemotherapy treatment. "ABT-737 would overcome resistance to chemotherapy that we often see in AML therapy, and the second drug would overcome resistance to ABT-737," he said.

"ABT-737 represents a completely new class of agents that could have a major impact on a number of cancers, and we have now seen that AML will likely be among them," Andreeff added.

The successful use of ABT-737 in animal models of human small-cell lung cancer and cancers of the lymph system were reported in 2005 by researchers from Abbott Laboratories, which developed the compound.

The agent works by manipulating members of the BCL-2 family of proteins, which includes both pro-apoptotic and anti-apoptotic molecules. (Apoptosis is a process whereby a cell kills itself because it is seriously injured or growing out of control).

ABT-737 targets the best-known member of the group, also called BCL-2, which is a cell "survival" protein that is over-expressed in many types of cancer. This protein prevents a cell from committing apoptosis by latching on to other BCL-2 family member proteins that promote cell death, thus rendering them ineffective. ABT-737, however, was engineered to fit tightly on to BCL-2, occupying that binding space so that the other pro-apoptotic proteins can function and promote cell death.

In this study, Andreeff and a team of researchers found that ABT-737 "potently" kills AML cell lines as well as blast cells taken from AML patients. "Most importantly, our results demonstrated killing of the progenitor and stem cells responsible for production of AML, which makes this a truly innovative treatment for different leukemias and cancer," Andreeff said.

However, AML cells in which another anti-apoptotic protein known as MCL-1 is over expressed did not die, which makes this protein a "resistance factor" to ABT-737 and to standard chemotherapy, he said. "In myeloid leukemia, MCL-1 can be more important than BCL-2 because when a cell has a significant amount of MCL-1, many drugs don't work," said Andreeff. In fact, he added, patients whose cells over-express MCL-1 were found by his group to have a poorer outcome.

So, the researchers added an experimental drug, a MAP-kinase inhibitor, to knock down MCL-1 expression, and found that this inhibitor also worked to inhibit cells in which BCL-2 is phosphorylated, which can switch a protein on or off. "ABT-737 had diminished effects against cells with phosphorylated BCL-2, which was restored by combination with a MAPK inhibitor," Andreeff said.

The study helps refine the understanding of the effects of ABT-737 on cancer cells, he said.

By using knock-out technology, the researchers also found that in leukemia cells, ABT-737 was dependent on two proteins called BAX and BAK to trigger apoptosis. Other researchers have said that the critical partner to ABT-737 was a similar protein known as BIM. "Both of these proteins poke holes in a cell mitochondria and release proteins that initiate cell death, but it is important to know that BAX and BAK are the important players," he said.

Andreeff said that the next step for M. D. Anderson researchers is to test ABT-737 in patients with leukemias.

Julie A. Penne | EurekAlert!
Further information:

Further reports about: ABT-737 AML Andreeff Bcl-2 Mcl-1 Protein chemotherapy leukemia

More articles from Life Sciences:

nachricht International team discovers novel Alzheimer's disease risk gene among Icelanders
24.10.2016 | Baylor College of Medicine

nachricht New bacteria groups, and stunning diversity, discovered underground
24.10.2016 | DOE/Lawrence Berkeley National Laboratory

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

New method increases energy density in lithium batteries

24.10.2016 | Power and Electrical Engineering

International team discovers novel Alzheimer's disease risk gene among Icelanders

24.10.2016 | Life Sciences

New bacteria groups, and stunning diversity, discovered underground

24.10.2016 | Life Sciences

More VideoLinks >>>